KR20210071944A - 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 - Google Patents

인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20210071944A
KR20210071944A KR1020217003239A KR20217003239A KR20210071944A KR 20210071944 A KR20210071944 A KR 20210071944A KR 1020217003239 A KR1020217003239 A KR 1020217003239A KR 20217003239 A KR20217003239 A KR 20217003239A KR 20210071944 A KR20210071944 A KR 20210071944A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217003239A
Other languages
English (en)
Korean (ko)
Inventor
로버트 더블유. 킨
더블유. 달톤 디트리치
리베로 바카리 후안 파블로 데
헬렌 엠. 브람레트
로버타 브람빌라
Original Assignee
더 유니버시티 오브 마이애미
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/026,482 external-priority patent/US10703811B2/en
Application filed by 더 유니버시티 오브 마이애미 filed Critical 더 유니버시티 오브 마이애미
Publication of KR20210071944A publication Critical patent/KR20210071944A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020217003239A 2018-07-03 2019-07-03 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 Ceased KR20210071944A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/026,482 US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis
US16/026,482 2018-07-03
PCT/US2019/040635 WO2020010273A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammasome related diseases or conditions

Publications (1)

Publication Number Publication Date
KR20210071944A true KR20210071944A (ko) 2021-06-16

Family

ID=78823964

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003239A Ceased KR20210071944A (ko) 2018-07-03 2019-07-03 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법

Country Status (16)

Country Link
US (1) US12570735B2 (https=)
EP (1) EP3818081A4 (https=)
JP (2) JP7824030B2 (https=)
KR (1) KR20210071944A (https=)
CN (1) CN113316588B (https=)
AU (1) AU2019297515A1 (https=)
BR (1) BR112020026798A2 (https=)
CA (1) CA3105129A1 (https=)
CL (1) CL2020003447A1 (https=)
CO (1) CO2021001172A2 (https=)
IL (1) IL279851A (https=)
MX (1) MX2021000142A (https=)
PH (1) PH12020552286A1 (https=)
SG (1) SG11202013176VA (https=)
WO (1) WO2020010273A1 (https=)
ZA (2) ZA202100703B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240060995A1 (en) * 2012-02-06 2024-02-22 University Of Miami Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
WO2021222263A2 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
RU2019123160A (ru) 2016-12-29 2021-01-29 Юниверсити Оф Майами Способ модуляции активности инфламмасом и воспаления в легком
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions
AU2022390134A1 (en) * 2021-11-16 2024-05-16 Ac Immune Sa Novel molecules for therapy and diagnosis
EP4583974A1 (en) * 2022-09-09 2025-07-16 University of Miami Inflammasome antibody compositon and method for treating neurologic disorder
WO2024114906A1 (en) * 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
WO2026042012A1 (en) * 2024-08-19 2026-02-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Single domain antibodies and polypeptides containing same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763849B1 (fr) 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7611707B2 (en) 2004-04-29 2009-11-03 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods thereof
WO2005111283A1 (ja) * 2004-05-17 2005-11-24 Denki Kagaku Kogyo Kabushiki Kaisha ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪
US7811563B2 (en) 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CA2623565A1 (en) 2005-09-28 2007-04-05 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
WO2010003092A1 (en) * 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2475380A1 (en) 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
IT1406201B1 (it) 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
EP2684051B1 (en) 2011-03-11 2016-04-27 Roche Diagniostics GmbH Asc as marker for chronic obstructive pulmonary disease (copd)
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
EP2812697B1 (en) 2012-02-06 2017-03-22 University of Miami Innate immune proteins as biomarkers for cns injury
TWI480044B (zh) 2012-03-16 2015-04-11 Taichung Veterans General Hospital A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
HK1219512A1 (zh) 2013-05-17 2017-04-07 F. Hoffmann-La Roche Ag 用於诊断和治疗炎性肠病的方法
JP6359013B2 (ja) * 2013-07-29 2018-07-18 国立大学法人 鹿児島大学 １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3183582B1 (en) 2014-08-18 2020-02-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
CN114699409A (zh) 2014-10-16 2022-07-05 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
US20160263183A1 (en) 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
AU2016260190A1 (en) 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis
US10195170B2 (en) 2015-08-17 2019-02-05 Twi Biotechnology, Inc. Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs
KR101948048B1 (ko) 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
RU2019123160A (ru) * 2016-12-29 2021-01-29 Юниверсити Оф Майами Способ модуляции активности инфламмасом и воспаления в легком
US11840565B2 (en) * 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
US10755739B1 (en) 2016-12-30 2020-08-25 John Fristrom Remote railway crossing programmable device and methods thereof
WO2019060516A1 (en) 2017-09-20 2019-03-28 University Of Miami METHOD FOR DETECTION OF INFLAMMASOME PROTEINS AS BIOMARKERS OF NEUROLOGICAL DISORDERS
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions

Also Published As

Publication number Publication date
SG11202013176VA (en) 2021-01-28
CN113316588B (zh) 2025-02-28
PH12020552286A1 (en) 2021-06-21
BR112020026798A2 (pt) 2021-03-30
ZA202100703B (en) 2022-08-31
MX2021000142A (es) 2021-05-12
JP2025067915A (ja) 2025-04-24
AU2019297515A1 (en) 2021-02-25
CA3105129A1 (en) 2020-01-09
CL2020003447A1 (es) 2021-07-30
ZA202201437B (en) 2024-05-30
JP2021528092A (ja) 2021-10-21
EP3818081A1 (en) 2021-05-12
CO2021001172A2 (es) 2021-07-09
EP3818081A4 (en) 2022-06-22
JP7824030B2 (ja) 2026-03-04
IL279851A (en) 2021-03-01
WO2020010273A1 (en) 2020-01-09
CN113316588A (zh) 2021-08-27
US12570735B2 (en) 2026-03-10
US20210284723A1 (en) 2021-09-16
JP7850296B2 (ja) 2026-04-22

Similar Documents

Publication Publication Date Title
US10961306B2 (en) Methods for treating lung inflammation with an anti-ASC antibody
JP7850296B2 (ja) インフラマソームに関連する疾患又は病態を治療するための組成物及び方法
CN110582511B (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
TWI702233B (zh) 抗TrkA抗體
US11840565B2 (en) Methods and compositions for treating virus-associated inflammation
US20230238030A1 (en) Methods for modulating inflammasome activity and inflammation in the lung
EP4393949A1 (en) Pharmaceutical composition containing fusion protein
CN119654161A (zh) 抗igf-1r抗体组合物
HK40055003A (zh) 用於治疗炎性小体相关疾病或病症的组合物和方法
US20240124570A1 (en) Inflammasome antibody compositon and method for treating neurologic disorder
RU2790561C2 (ru) Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания
JP2025530202A (ja) 神経疾患を治療するためのインフラマソーム抗体組成物及び方法
HK40016017A (en) Method for modulating inflammasome activity and inflammation in the lung

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000